{"doi":"10.1002/oby.23869","title":"Use and continuity of weight‐modifying medications among adults with diabetes and overweight/obesity: US population study","abstract":"OBJECTIVE: Trends in use and continuity of use of diabetes-specific and non-diabetes weight-reducing (WR), weight-inducing (WI), and weight-neutral (WN) medications were examined among US adults with diabetes and overweight/obesity. METHODS: for Asians) were analyzed. RESULTS: Among 7402 US adults with diabetes and overweight/obesity (mean age 60.0 years [SD 13], 50% female), 64.9% of participants used any WI medications, decreasing from 68.9% (95% CI: 64.3%-73.5%) in 2010 to 58.6% (95% CI: 54.7%-62.5%) in 2019. It was estimated that 13.5% used WR medications, increasing 3.31-fold, from 6.4% (95% CI: 4.1%-8.7%) to 21.2% (95% CI: 18.0%-24.4%) and that 73.1% used WN medications, ranging from 70.5% (95% CI: 66.5-74.6) to 75.0% (95% CI: 71.7%-78.4%). Among adults using diabetes-specific WI (53.7%), WR (7.1%), and WN (62.4%) medications during the first year, 7.3%, 16.4%, and 9.0% discontinued it in the second year, respectively. CONCLUSIONS: Over 2010-2019, 64.9% of adults with diabetes and overweight/obesity were treated with WI medications, 13.5% with WR medications, and 73.1% with WN medications. Discontinuation of WR medications was nearly twice that of WI medications.","journal":"Obesity","year":2023,"id":343539,"datarank":0.6516771857472199,"base_score":2.70805020110221,"endowment":2.70805020110221,"self_citation_contribution":0.40620753016533157,"citation_network_contribution":0.2454696555818883,"self_endowment_contribution":0.40620753016533157,"citer_contribution":0.2454696555818883,"corpus_percentile":69.46700703952966,"corpus_rank":3948,"citation_count":14,"citer_count":10,"citers_with_citation_signal":9,"citers_with_endowment":9,"datacite_reuse_total":0,"is_dataset":true,"is_dataset_confidence":0.5455,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":955577,"name":"Tegveer S. Uppal","orcid":null,"position":1,"is_corresponding":false},{"id":306790,"name":"Rozalina G. McCoy","orcid":"0000-0002-2289-3183","position":2,"is_corresponding":false},{"id":228523,"name":"Guillermo E. Umpierrez","orcid":"0000-0002-3252-5026","position":3,"is_corresponding":false},{"id":22946,"name":"Mohammed K. Ali","orcid":"0000-0001-7266-2503","position":4,"is_corresponding":false},{"id":249469,"name":"Rodolfo J. Galindo","orcid":"0000-0002-9295-3225","position":0,"is_corresponding":true}],"reference_count":42,"raw_metadata":null,"created_at":"2026-07-19T01:11:21.758449Z","pmid":"37919239","pmcid":"PMC10840906","fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}